First implantation of WiCS wireless cardiac pacing system performed in Germany

EBR Systems, Inc., a privately held clinical stage company, announced today the first human implants of the WiCS® Wireless Cardiac Stimulation System. The WiCS® cardiac pacing system represents a significant medical breakthrough, eliminating the cardiac pacing lead by stimulating the heart through wireless transmission of energy. This technology has the potential to revolutionize the future of cardiac pacing. These first implants mark the beginning of the WiSE-CRT (Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy) clinical trial sponsored by EBR Systems.

The first human implant in the world occurred at Isala Kilinieken in Zwolle, NL, by Dr. Peter Paul Delnoy. The patient, who met clinical guidelines for cardiac resynchronization therapy (CRT), was a 69 year old male with ischemic heart disease, class 3 heart failure and prolonged QRS who had a previously implanted St Jude Medical dual chamber ICD (in 2008). The WiCS wireless cardiac stimulation system, together with the previously implanted dual chamber ICD, successfully upgraded the patient to cardiac resynchronization therapy, without disruption or premature replacement of the functional ICD system. Thirty day follow-up of the patient and the system demonstrated acute CRT pacing confirmed electrically by EKG and hemodynamically by echocardiography. Dr. Delnoy also implanted a second upgrade patient, a 65 year old patient meeting standard guidelines for CRT and had a previously implanted Medtronic ICD.

Dr Christian Butter at Herzzentrum Brandenburg Hospital in Bernau bei Berlin performed the first two implants of the WiCS system in Germany. The system was implanted in a 59 year old male with ischemic heart disease, also as part of the WiSE-CRT trial. The WiCS system was co-implanted with a previously implanted Medtronic CRT device (in 2008). The coronary sinus (CS) lead implanted in 2008 with the CRT device had stopped pacing the heart, and a thrombotic occlusion precluded replacement of the CS lead, despite attempts to re-open the occluded vein. The use of WiCS pacing system allowed an alternative to the coronary sinus lead to deliver CRT therapy. Following successful implantation of the WiCS system, the patient demonstrated successful biventricular pacing and capture of the left ventricle, as evidenced by EKG morphology changes and shortening of the QRS complex. The second patient, a 78 year old male with ischemic heart disease, and left ventricular ejection fraction (EF) of 25% was also implanted with the WiCS pacing system. This patient had been previously implanted with a Medtronic CRT system, however, infection required explantation of the pacing lead, and no CS lead was able to be re-implanted, despite multiple attempts by several different physicians. Patient follow up was done prior to discharge confirming a successful implant and delivery of CRT therapy.

"Both of these patients had previous attempts to implant cardiac resynchronization therapy that failed, due to the challenges and limitations of implanting left heart leads through the coronary sinus. Implanting a wireless electrode in the left ventricle provides a solution for many patients previously being denied therapy," said Dr. Christian Butter, Chief of Cardiology, Herzzentrum Brandenburg.

"We are excited to have achieved this important milestone in the field of cardiac rhythm management, the elimination of a pacing lead for cardiac stimulation. 2011 marks the beginning of a new era in cardiac pacing and opens up a wide range of opportunities, WiCS will play an important role in changing cardiac stimulation therapy enabling multi-site stimulation, site specific pacing, and leadless pacing," said Rick Riley, CEO EBR Systems, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Coronary artery calcium scores found to predict risk of heart attack and death in both men and women